BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 30449032)

  • 21. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine.
    Müller F; König J; Hoier E; Mandery K; Fromm MF
    Biochem Pharmacol; 2013 Sep; 86(6):808-15. PubMed ID: 23876341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
    Robert M; Frenel JS; Bourbouloux E; Berton Rigaud D; Patsouris A; Augereau P; Gourmelon C; Campone M
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):85-91. PubMed ID: 30577708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways.
    Liu Y; Zhao R; Fang S; Li Q; Jin Y; Liu B
    Fundam Clin Pharmacol; 2021 Feb; 35(1):156-164. PubMed ID: 32446293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.
    Med Lett Drugs Ther; 2017 Nov; 59(1533):185-186. PubMed ID: 29125595
    [No Abstract]   [Full Text] [Related]  

  • 26. Impact of Substrate-Dependent Inhibition on Renal Organic Cation Transporters hOCT2 and hMATE1/2-K-Mediated Drug Transport and Intracellular Accumulation.
    Yin J; Duan H; Wang J
    J Pharmacol Exp Ther; 2016 Dec; 359(3):401-410. PubMed ID: 27758931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.
    Pabla N; Gibson AA; Buege M; Ong SS; Li L; Hu S; Du G; Sprowl JA; Vasilyeva A; Janke LJ; Schlatter E; Chen T; Ciarimboli G; Sparreboom A
    Proc Natl Acad Sci U S A; 2015 Apr; 112(16):5231-6. PubMed ID: 25848011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis.
    Desnoyers A; Nadler MB; Kumar V; Saleh R; Amir E
    Cancer Treat Rev; 2020 Nov; 90():102086. PubMed ID: 32861975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
    El Hachem G; Gombos A; Awada A
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):81-92. PubMed ID: 33054442
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney.
    Ito S; Kusuhara H; Yokochi M; Toyoshima J; Inoue K; Yuasa H; Sugiyama Y
    J Pharmacol Exp Ther; 2012 Feb; 340(2):393-403. PubMed ID: 22072731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.
    Lim JS; Turner NC; Yap TA
    Cancer Discov; 2016 Jul; 6(7):697-9. PubMed ID: 27371575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Population Pharmacokinetic and Pharmacodynamic Analysis of Abemaciclib in a Phase I Clinical Trial in Cancer Patients.
    Tate SC; Sykes AK; Kulanthaivel P; Chan EM; Turner PK; Cronier DM
    Clin Pharmacokinet; 2018 Mar; 57(3):335-344. PubMed ID: 28540640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non-Small Cell Lung Cancer
    Naz S; Sowers A; Choudhuri R; Wissler M; Gamson J; Mathias A; Cook JA; Mitchell JB
    Clin Cancer Res; 2018 Aug; 24(16):3994-4005. PubMed ID: 29716919
    [No Abstract]   [Full Text] [Related]  

  • 34. Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K.
    Yin J; Wagner DJ; Prasad B; Isoherranen N; Thummel KE; Wang J
    Am J Physiol Renal Physiol; 2019 Oct; 317(4):F805-F814. PubMed ID: 31322418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N(1)-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction.
    Müller F; Pontones CA; Renner B; Mieth M; Hoier E; Auge D; Maas R; Zolk O; Fromm MF
    Eur J Clin Pharmacol; 2015 Jan; 71(1):85-94. PubMed ID: 25552403
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
    Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
    Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
    Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
    Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Involvement of Renal Efflux Transporter MATE1 in Renal Excretion of Flecainide.
    Doki K; Apáti S; Sakata T; Homma M
    Biol Pharm Bull; 2019; 42(7):1226-1229. PubMed ID: 31257298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
    Franzoi MA; Eiger D; Ameye L; Ponde N; Caparica R; De Angelis C; Brandão M; Desmedt C; Di Cosimo S; Kotecki N; Lambertini M; Awada A; Piccart M; Azambuja E
    J Natl Cancer Inst; 2021 Apr; 113(4):462-470. PubMed ID: 32750143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Importance of OCT2 and MATE1 for the Cimetidine-Metformin Interaction: Insights from Investigations of Polarized Transport in Single- And Double-Transfected MDCK Cells with a Focus on Perpetrator Disposition.
    Müller F; Weitz D; Mertsch K; König J; Fromm MF
    Mol Pharm; 2018 Aug; 15(8):3425-3433. PubMed ID: 29975542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.